{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-25.6","upperLimit":"39.3","value":"-8.84"},{"groupId":"OG001","lowerLimit":"-157.2","upperLimit":"-1.4","value":"-6.62"}]}],"title":"Month 2.75"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-22.2","upperLimit":"39.3","value":"-6.71"},{"groupId":"OG001","lowerLimit":"-99.2","upperLimit":"-1.4","value":"-5.04"}]}],"title":"Month 3"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-25.4","upperLimit":"39.3","value":"-8.15"},{"groupId":"OG001","lowerLimit":"-149.8","upperLimit":"-1.4","value":"-6.35"}]}],"title":"Month 6"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-24.6","upperLimit":"39.3","value":"-9.02"},{"groupId":"OG001","lowerLimit":"-163.8","upperLimit":"1.8","value":"-8.72"}]}],"title":"Month 9"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-29.1","upperLimit":"3.0","value":"-10.10"},{"groupId":"OG001","lowerLimit":"-159.2","upperLimit":"-1.4","value":"-7.29"}]}],"title":"Month 12"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-23.9","upperLimit":"39.3","value":"-8.88"},{"groupId":"OG001","lowerLimit":"-155.7","upperLimit":"-0.3","value":"-7.70"}]}],"title":"Month 18"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-25.5","upperLimit":"39.3","value":"-9.76"},{"groupId":"OG001","lowerLimit":"-32.8","upperLimit":"-1.4","value":"-6.80"}]}],"title":"Month 24"}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"description":"This shows a change of mean GH levels and somatostatin analogues (SSAs) from baseline in extension phase","dispersionType":"Full Range","groups":[{"description":"Somatostatin analogue (SSA) uncontrolled population composes of patients who were pre-treated with SSA for \\>= 12 weeks.","id":"OG000","title":"SSA Uncontrolled"},{"description":"Patients who were pre-treated with SSA for \\< 12 weeks or were not pre-treated with SSA are considered as others.","id":"OG001","title":"Others"}],"paramType":"MEDIAN","populationDescription":"FAS: Comprises all patients to whom study treatment has been assigned by randomization. According to the intent to treat principle, patients were analyzed according to the study treatment they have been assigned to during the randomization procedure.","reportingStatus":"POSTED","timeFrame":"Baselnine, Months 2.75, 3, 6, 9, 12, 18, 24","title":"Change From Baseline in Mean GH by Visit and SSA Uncontrolled Status (Extension Phase)","type":"SECONDARY","unitOfMeasure":"ug/L"}